|Bid||37.83 x 1000|
|Ask||38.68 x 800|
|Day's Range||36.89 - 38.78|
|52 Week Range||36.21 - 51.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If Sound Pharmaceuticals makes its IPO, it would be a positive signal for Seattle's biotech scene, says an industry expert.
Adaptive Biotechnologies Corporation (ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to improve patient lives, today announced the closing of its initial public offering of 15,000,000 shares of common stock, and the exercise in full of the underwriters’ option to purchase 2,250,000 additional shares of its common stock, at a public offering price of $20.00 per share. Goldman Sachs & Co. LLC, J.P. Morgan and BofA Merrill Lynch acted as joint lead book-running managers for the offering.
MarketWatch spoke with Adaptive Biotechnologies’ Chief Executive Chad Robins about the IPO, what’s next for the company and what it’s like working with his older brother.
(Bloomberg) -- Two brothers banking on a novel approach to diagnosing disease are behind the splashiest stock-market debut by a biotechnology company this year.Adaptive Biotechnologies Corp. saw its shares more than double in value in their first day of trading Thursday on the Nasdaq Stock Market, after pricing at $20 in their initial public offering. The surge left Seattle-based Adaptive with a valuation of roughly $4.9 billion. The launch is the latest in a recent run of successful market premieres for innovative health-care companies.The company has a grand vision of building a map of the immune system that would allow doctors to diagnose virtually any disease -- from Lyme to multiple sclerosis to cancer, ideally in the earliest stages -- through a simple blood draw.Adaptive is the brainchild of Harlan Robins, 46, a medical researcher who holds a doctorate in theoretical physics from the University of California, Berkeley, and Chad Robins, 45, a former hedge-fund trader with an MBA from the Wharton School of Business.After earning his Ph.D., Harlan had turned down opportunities to make millions as a quant on Wall Street. By 2009, he was working as a researcher at Fred Hutchinson Cancer Research Center in Seattle, when he called Chad with the idea of starting a company. Chad was focused on real estate, not health care. He knew little about his brother’s research, but he said yes.A decade later, the Robins brothers are enjoying a windfall: Together, they own almost 7% of Adaptive, a stake worth roughly $337 million after Thursday’s pop. Chad, who is the company’s chief executive officer, holds a larger stake than Harlan.Cell SignalsWhen a patient is in the early stages of disease, markers of the illness called antigens appear on the surface of the pathogen. T-cells, or white blood cells, detect those signals and organize a response. The signatures on the cells’ surface can reveal whether a patient’s body is fighting off Lyme or ovarian cancer, for example.Using recent advances in genetic sequencing and increased computational power, Adaptive is hoping to be able to identify those signals in order to better diagnose many diseases.Adaptive is hoping to build a database of the immune system that would allow doctors to diagnose a whole set of disorders with one test. Chad Robins said in an interview that he envisions physicians using it in much the same way investment bankers use Excel.Building such a database requires mathematical know-how, huge computational wherewithal and cash. While Harlan focused on building the company’s research capabilities, Chad criss-crossed the country raising money from friends, family and institutional investors.Adaptive is further along than many biotechnology companies that have recently sold shares to public investors. It already has two products on the market, unlike many peers that are often years away from selling anything when they IPO. While still private, Adaptive closed deals with Microsoft Corp. and cancer giant Genentech.Robust MarketsAdaptive benefited from robust capital markets that have sent valuations of young companies soaring.The company raised $300 million through its listing, a figure that might have been an industry record several years ago but is becoming routine. Bridgebio Pharma Inc., which made its debut on Thursday alongside Adaptive, is now valued at about $3.3 billion after raising $348.5 million in its initial offering.Meanwhile, investors from Third Rock Ventures to Bain Capital to Blackstone Group LP have raised ever-larger funds to pour into the industry. Bulls argue that the science behind upstart biotechs is more advanced than ever and that tests like Adaptive’s are years, not decades, from reality. Bears say immature and unproven companies are raising too much money too early in their development.Either way, the capital markets remain open for now. For its part, Adaptive says it is focused on the science.“I see the IPO as just one more step in the process,” Chad said. “We have so much more to accomplish.”To contact the reporter on this story: Rebecca Spalding in Boston at email@example.comTo contact the editors responsible for this story: Drew Armstrong at firstname.lastname@example.org, Timothy Annett, Mark SchoifetFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
the Seattle company seeking to use the genetics of the immune system in life-sciences research and drug development, doubled on Thursday, their first day of trading. On Wednesday Adaptive priced an IPO of 15 million shares at $20, exceeding the estimated range of $18 to $19 a share and an earlier estimate of $15 to $17. The underwriters have a 30-day option on 2.25 million more shares at the IPO price.
Shares of Adaptive Biotechnologies Corp. rocketed in their public debut Thursday, as investors flocked to the life-sciences research company that’s looking to the immune system to cure the world’s ills. The $18-to$19 estimate was already a boost from the company’s original pricing range of between $15 and $17 a share. Adaptive, a life-sciences research and clinical diagnostics company, believes data from the immune system is the key to diagnosing and treating diseases.
Adaptive Biotechnologies Corp. shares rocketed 96% in their first ten minutes of trade Thursday, after the company priced its initial public offering above its price range. The life-sciences research and clinical diagnostics company that says data from the immune system is the key to diagnosing and treating diseases, priced its IPO at $20 a share, bove the pricing range it gave early Wednesday of between $18 and $19, which was already a boost from the company's original pricing range of between $15 and $17 a share. Adaptive sold 15 million shares to raise $300 million, and shares are trading on the Nasdaq under the symbol ADPT. The stock of BridgeBio Pharma Inc. , meanwhile, soared more than 70% in its trading debut. That company also priced its IPO above the price range, selling 20.5 million shares priced at $17 each to raise $348.6 million. The price range was $14 to $16. The stock is trading on Nasdaq, under the ticker symbol "BBIO."
Adaptive Biotechnologies Corp. , a life-sciences research and clinical diagnostics company that says data from the immune system is the key to diagnosing and treating diseases, has priced its IPO at $20 a share. That's above the pricing range it gave early Wednesday of between $18 and $19, which was already a boost from the company's original pricing range of between $15 and $17 a share. Adaptive sold 15 million shares in its public debut to raise $300 million, and shares will begin trading Thursday on the Nasdaq under the symbol ADPT.
ADVISORY, June 27, 2019 -- What: Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that reads and translates the genetic code of.
SEATTLE, June 26, 2019 -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code.
Adaptive Biotechnologies Corp. increased the number of shares it will sell in its initial public offering, and the expecting pricing range increased as well, according to a filing with the Securities and Exchange Commission on Wednesday. The company is now offering 15 million shares, up from 12.5 million shares disclosed last week, while the expected pricing range is now $18 to $19 a share, up from $15 to $17 a share. The developer of immune-system derived disease treatments is now looking to raise $285 million, and be valued at up to $2.30 billion, before underwriters exercise any options to buy up to an additional 2.25 million shares. The upsized IPO comes at a time that the Renaissance IPO ETF has gained 2.0% over the past three months, the iShares Nasdaq Biotechnology ETF has slipped 2.9% and the S&P 500 has advanced 3.9%.
Adaptive Biotechnologies is planning to offer 12.5 million shares in an IPO to be priced between $15 and $17, according an amended filing dated June 19. Adaptive Biotechnologies, founded in 2009, focuses on developing immune-driven medicines by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Technologies reported 45% year-over-year revenue growth to $55.66 million in 2018.
Adaptive Biotechnologies Corp. set terms for its initial public offering Monday, in which the developer of immune-system derived disease treatments is expected to raise up to $212.5 million and be valued at about $2.01 billion. The Seattle-based company is offering 12.5 million shares in the IPO, which is expected to price between $15 and $17 a share. If the underwriters, led by Goldman Sachs, J.P. Morgan and BofA Merrill Lynch, exercise all options to buy 1.875 million additional shares, the company could raise up to $244.4 million and be valued at up to $2.05 billion. The stock is expected to list on the Nasdaq under the ticker symbol "ADPT." The underwriters are led by Goldman Sachs, Citigroup and Wells Fargo Securities. After the IPO, the company will have about 118.5 million shares outstanding. The company recorded a net loss of $46.3 million on revenue of $55.7 million in 2018, after a loss of $42.5 million on $38.4 million in revenue in 2017. The company is looking to go public at a time that the iShares Nasdaq Biotechnology ETF has gained 10% year to date and the S&P 500 has advanced 15%.
The IPO market is heating up as the healthcare and biotech sectors take center stage. Yahoo Finance's Zack Guzman & Kristin Myers discuss with New Constructs Investment Analyst Sam McBride.
Adaptive Biotechnologies increased the number of shares it will sell in its initial public offering. Yahoo Finance's Ines Ferre has the story.